Previous close | 43.54 |
Open | 42.10 |
Bid | 40.34 x 0 |
Ask | 0.00 x 0 |
Day's range | 42.01 - 42.33 |
52-week range | 33.78 - 48.18 |
Volume | |
Avg. volume | 210,470 |
Market cap | 10.721B |
Beta (5Y monthly) | 0.39 |
PE ratio (TTM) | 32.25 |
EPS (TTM) | 1.35 |
Earnings date | 06 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
QIAGEN's (QGEN) solid potential in the NGS platform buoys optimism for investors.
QIAGEN's (QGEN) Clinical Insight Interpret is the first NGS interpretation platform approved by IVDR for use in cancer and hereditary applications.
As the first NGS interpretation platform for both oncology and hereditary applications, the updated version of QIAGEN Clinical Insight Interpret is approved for diagnostic use // Regulatory framework ensures greater patient protection, transparency of information, and traceability of data // Over 4 million NGS patient test cases for oncology and hereditary diseases worldwide processed with QIAGEN Clinical Insight InterpretVenlo, the Netherlands, May 14, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGE